Alkermes reports 30% rise in sales of key drug
Company pulls full-year guidance on coronavirus disruption to healthcare systems
Losses dip slightly at Alkermes to $72.6m
Dublin-headquartered biopharma company saw rise in revenues for quarter to $191.8m
Alkermes executives take a hit on pay package
Irish-domiciled biopharma group reported 31% rise in sales last year
Alkermes loss rises to $77m in first quarter
Biopharma company reports sales of $156 million, down from $161 million in 2015
Alkermes looks to schizophrenia drug approval as sales jump 24%
Heavy investment in R&D and set-up costs for new therapies push biopharma group to $30.6m loss
YOU MAY ALSO LIKE...
Crosswords & Puzzles
Crosswords & puzzles to keep you challenged and entertained
Election 2024
Full general election coverage including analysis and results for all 43 constituencies
Common Ground
How does a post-Brexit world shape the identity and relationship of these islands
Family NoticesOpens in new window
Weddings, Births, Deaths and other family notices